Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) will likely be posting its results before the market opens on Tuesday, November 3rd. Analysts expect Coloplast A/S to announce earnings of $0.0898 per share and revenue of $1.12 billion for the quarter.
Coloplast A/S (OTCMKTS:CLPBY – Get Free Report) last announced its earnings results on Tuesday, August 18th. The company reported $0.10 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.10. The company had revenue of $1.14 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Coloplast A/S had a return on equity of 39.27% and a net margin of 9.68%. On average, analysts expect Coloplast A/S to post $0.40 EPS for the current fiscal year and $0.41 EPS for the next fiscal year.
Coloplast A/S Stock Down 1.2%
Shares of OTCMKTS:CLPBY opened at $7.24 on Tuesday. The business’s 50 day moving average is $6.78 and its 200 day moving average is $6.86. Coloplast A/S has a 12-month low of $5.64 and a 12-month high of $9.70. The stock has a market cap of $16.32 billion, a price-to-earnings ratio of 38.11, a PEG ratio of 2.61 and a beta of 0.21. The company has a quick ratio of 0.94, a current ratio of 1.56 and a debt-to-equity ratio of 1.51.
Coloplast A/S Company Profile
Coloplast A/S is a Denmark-based medical technology company that develops, manufactures and markets products designed to help people manage intimate health conditions. Its core businesses include ostomy care, continence care, wound and skin care, and interventional urology. The company’s products are used by patients and healthcare professionals in hospitals, clinics and home-care settings.
Coloplast was founded in Denmark in 1957 after nurse Elise Sørensen helped develop an adhesive ostomy bag for her sister, who had undergone surgery.
See Also
- Five stocks we like better than Coloplast A/S
- A Solid Margin Story Means the Sell-Off in DECK May Be Overdone
- Verizon’s Q3 Results Show Why SpaceX’s Spectrum Grab Isn’t a Major Threat
- Comfort Systems Earnings: AI Slowdown or More Growth Ahead?
- Bristol Myers Squibb’s Cancer Breakthrough Could Have Implications Beyond Its Own Stock
Receive News & Ratings for Coloplast A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Coloplast A/S and related companies with MarketBeat.com's FREE daily email newsletter.
